Infographic Design Information  
For requests to submit to DesignCrowd

|  |  |
| --- | --- |
| Study information | Answer |
| Study title | Platelet rich Plasma in Achilles Tendon Healing 2 (PATH-2) trial |
| Study acronym | PATH-2 |
| Headline | Does an injection of platelet rich plasma improve outcomes after acute Achilles tendon rupture? |
| Study summary | This study tested whether a platelet-rich plasma (PRP) injection improves outcomes after an Achilles tendon rupture. It was a randomised controlled trial, where adults with acute tendon ruptures (treated without surgery) were randomly assigned to receive either a PRP injection or a placebo injection, along with standard rehabilitation. Researcher’s main outcome was muscle-tendon function measured by the heel-rise endurance test (HRET) after 24 weeks. Patient-reported function, pain, quality of life, and other recovery outcomes were assessed at 4, 7, 13 and 24 weeks, and also at two-years. |
| Key messages/findings | The outcome measures showed no evidence to indicate that injections of platelet rich plasma improve objective muscle-tendon function after acute Achilles tendon rupture compared with placebo, or that they offer any patient benefit. |
| Eligibility criteria (if relevant) | Adults aged 18 years and over with acute Achilles tendon rupture, presenting within 12 days of injury and managed with non-surgical treatment. |
| Study details (if relevant) | - 19 hospital sites across the UK - 230 participants were recruited to the study  - Primary outcome measure: muscle-tendon function at 24 weeks Secondary outcome measures: patient reported ankle function, quality of life, pain, goal attainment, and adverse events. A central laboratory analysed the quality and content of platelet rich plasma.  - 202 (88%) participants completed the heel rise endurance test and 216 (94%) the patient reported outcomes at 24 weeks  - Two-year questionnaires were sent to 216 participants who completed a six-month questionnaire. Overall, 182/216 participants (84%) completed the two-year questionnaire. |
| Target audience | Patients, clinicians |
| Contact information | [oxfordtrauma@ndorms.ox.ac.uk](mailto:oxfordtrauma@ndorms.ox.ac.uk) |
| Sponsor name | University of Oxford |
| Funder | Efficacy and Mechanism Evaluation programme, a Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR) partnership (reference 12/206/30), supported by the NIHR Oxford Biomedical Research Centre |

|  |  |  |
| --- | --- | --- |
| Design information/branding | Answer | Notes |
| Is this a WHiTE trial? | No |  |
| If not a WHiTE trial, what is the preferred colour scheme? | Colour scheme to be based on colours of PATH-2 study logo | Could be based on colours in the trial logo |
| Style and design preferences | Professional, clear, concise | E.g. clean / bold / clinical / friendly |

|  |  |  |
| --- | --- | --- |
| Additional notes for designer | Answer | Notes |
| Any other details to include in brief which is sent to designers |  |  |

NB the following logos will usually need to be included: trial logo, Oxford Trauma and Emergency Care, NDORMS (if applicable), NIHR (if NIHR-funded), University of Oxford (if applicable), Sponsor/NHS Trust (if applicable)